A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia

Trial Profile

A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Bitopertin (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 29 Mar 2014 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
    • 29 Mar 2014 Results published in the European Neuropsychopharmacology.
    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top